CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma

Abstract

BackgroundCyclin D1 (CCND1) has been associated with chemotherapy resistance and poor prognosis. In this study, we tested the hypothesis that CCND1 expression determines response and clinical outcomes in locally advanced head and neck squamous cell carcinoma (HNSCC) patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy.Methodology and Findings224 patients with HNSCC were treated with either cisplatin-based chemotherapy followed by surgery and radiotherapy (neoadjuvant group, n = 100) or surgery and radiotherapy (non-neoadjuvant group, n = 124). CCND1 expression was assessed by immunohistochemistry. CCND1 levels were analyzed with chemotherapy response, disease-free survival (DFS) and overall survival (OS). There was no significant difference between the neoadjuvant group and non-neoadjuvant group in DFS and OS (p = 0.929 and p = 0.760) when patients treated with the indiscriminate administration of cisplatin-based chemotherapy. However, in the neoadjuvant group, patients whose tumors showed a low CCND1 expression more likely respond to chemotherapy (p<0.001) and had a significantly better OS and DFS than those whose tumors showed a high CCND1 expression (73% vs 8%, p<0.001; 63% vs 6%, p<0.001). Importantly, patients with a low CCND1 expression in neoadjuvant group received more survival benefits than those in non-neoadjuvant group (p = 0.016), however patients with a high CCND1 expression and treated with neoadjuvant chemotherapy had a significantly poor OS compared to those treated with surgery and radiotherapy (p = 0.032). A multivariate survival analysis also showed CCND1 expression was an independent predictive factor (p<0.001).ConclusionsThis study suggests that some but not all patients with HNSCC may benefit from neoadjuvant chemotherapy with cisplatin-based regimen and CCND1 expression may serve as a predictive biomarker in selecting patients undergo less than two cycles of neoadjuvant chemotherapy.

RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma

“…In HNSCC, high cyclin D1 expression is correlated with chemotherapy failure and poor prognosis (30)(31)(32). In response to G12V HRAS-driven activation of the MAPK pathway, we observed a robust upregulation of cyclin D1 protein levels in UM-SCC1 cells, whereas cyclin D1 levels were only slightly upregulated in UM-SCC25 cells (Fig.…”

Galangin inhibits growth of human head and neck squamous carcinoma cells in vitro and in vivo

“…Upon phosphorylation, pRb releases the transcription factor E2F, which is then able to activate the transcription of genes required for G1/S phase transition [32]. It has been reported that cyclin D1 is overexpressed in many human cancers including HNSCC, and it is associated with enhanced tumor growth, chemotherapy resistance and poor prognosis [33][34][35]. Thus, suppression of cyclin D1 may be a useful target for the therapy of HNSCC.…”

Nodal Yield: Is it a Prognostic Factor for Head and Neck Squamous Cell Carcinoma?

“…Unfortunately, 75% of Chinese patients already have advanced-stage disease at the time of diagnosis, and more than 76,000 patients die each year. 1 It is well known that lymph node metastases are the most important prognostic factor in head and neck cancer. [2][3][4][5] Recently, it was reported that lymph node yield (LNY) was likely an independent prognostic factor in patients undergoing neck dissection for head and neck squamous cell carcinoma (HNSCC).…”